LONDON, July 25, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS)
("COMPASS"), a biotechnology company dedicated to accelerating patient access to
evidence-based innovation in mental health, today announced the publication of a
paper in Nature Medicine (https://www.nature.com/articles/s41591-
023-02455-9) that demonstrates the potential for COMP360 psilocybin treatment in
anorexia nervosa. The investigator-initiated open-label study was conducted by
Drs. Walter Kaye and Stephanie Knatz Peck at the University of California San
Diego School of Medicine and is believed to be the first clinical research study
to report the effects of psilocybin treatment in anorexia nervosa.
The study investigated the safety, efficacy, and tolerability of a single 25mg
dose of COMP360 psilocybin, with psychological support (referred to as
"psilocybin therapy" in the paper), in female patients with anorexia nervosa
(n=10). The results showed:

  * 40% (n=4) of participants experienced clinically significant reductions in
    eating disorder psychopathology at the three-month follow-up.

* Participants demonstrated statistically significant reductions from baseline in shape concerns at the one-month follow-up (pÂ